Dr. Brentjens on CD19-Targeted T Cells in CLL and ALL

2 Views
administrator
administrator
07/14/23

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center, discusses clinical responses in patients with chronic lymphoblastic leukemia (CLL) or acute lymphoblastic leukemia (ALL) following infusion with CD19-Targeted T Cells.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next